Heart condition patients with a slower heart rhythm will benefit significantly with the introduction of Abbott’s AVEIR™ VR leadless pacemaker as it has been approved by both the Central Drugs Standard Control Organization (CDSCO) and the U.S. FDA. There is no questioning that this device will revolutionize the treatment of cardiac care diseases as this device provides a solution for less invasive pacemakers.
What is So Impressive about AVEIR™ VR?
Abbott’s AVEIR™ VR is a remarkable leadless pacemaker, unique to the market as it can be implanted with pinpoint precision through a catheter-based procedure from the groin directly into the heart's right ventricle. This means that doctors are able to control the placement of the leadless pacemaker with ease, without the need for leads. This device has a projected battery life of over 20 years, which means many patients may not require a replacement battery for a long time.
The Advantages of Leadless Pacemaker Technology
Minimally Invasive Procedure: The AVEIR™ VR overcomes the need to open the chest cavity, as it does not require leads or a chest pocket. This reduces the chances of infection and complications related to traditional pacemaker implantation.
Long-Term Cost Effectiveness: The AVEIR™ VR system should be viewed as an economically favorable solution for managing cardiac health in the long term due to the pacemaker's durability and extended battery life.
Improved Patient Comfort and Safety: The absence of leads and chest incisions means fewer aesthetic concerns for patients and lowers the risk of complications like lead misplacement or vascular trauma.
Patient-Centric Features
The AVEIR™ VR's retrievability and unique mapping capability before final implantation are important factors in enhancing patient management during the modern era and in the future as patients’ medical conditions change over time.
The Future of Cardiac Care in India
It is anticipated that the introduction of AVEIR™ VR will address significant challenges in cardiac care for patients susceptible to bradyarrhythmia. As healthcare providers and patients seek more effective and safer treatment modalities, Abbott's innovation meets these needs with a device that is both durable and enhances quality of life.
Conclusion
The AVEIR™ VR leadless pacemaker by Abbott is more than just a pacemaker, it is an advancement in managing cardiac health. With its user-oriented engineering and cutting-edge technology, this device offers a glimpse into the future of treatment for heart rhythm disturbances in India and the world.
